Nonalcoholic Fatty Liver Disease (NAFLD) Adult Registry
Epidemiology of Fatty Liver as Measured by MRI and Lab Work
PI: Rohit Loomba
The purpose of the NAFLD Registry is to better understand nonalcoholic fatty liver disease (NAFLD) by following and evaluating people yearly with or without this condition. NAFLD is a common liver disease in the United States. The causes of NAFLD are unknown, but are probably due to different reasons, from inherited characteristics to personal lifestyle. Some reasons may increase the chance of developing NAFLD(these are called “risk factors”) while other reasons may decrease the chance of developing NAFLD (“protective factors”). The factors that determine whether a patient progresses from NAFLD to more severe liver disease are unknown. The time it takes for a patient to progress to more severe disease is also uncertain.
The NAFLD Registry will recruit 250 new adult participants suspected or known to have NAFLD or NASH-related cirrhosis. The Registry will also recruit 250 controls without NAFLD. Minimum follow-up on a participant will be 48 weeks, and maximum follow-up on a participant will be 192 weeks.
To be eligible for this study you must be at least 18 years old. You may have NAFLD or NASH-related cirrhosis or may serve as a control, a participant without this condition. You cannot have consumed significant amounts of alcohol within the past two years. We will ask you questions to check that you are not drinking significant amounts of alcohol during the study. If you are a woman of child-bearing potential, a pregnancy test will be administered. Pregnant women will be excluded from this study. Study participants will be asked to come in a fasting state for the blood draw and will receive a physical exam and undergo imaging (magnetic resonance techniques and ultrasound). In addition, participants will be asked questions about alcohol consumption and medication use.
Note: We are currently enrolling patients for this study.
Informed Consent Forms:
General Adult Consent
For additional questions regarding this study please contact:
Clinical Research Coordinator